{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-25-002927","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.490285+00:00","generated_at":"2026-05-17T17:08:19.253956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytoSorbents Q2 revenue $9.6M (+9% YoY); net income $1.9M but adjusted loss widens","bullets":["Revenue $9.6M, up 9% YoY (4% constant currency); Germany sales up 22% YoY and sequentially.","Net income $1.9M ($0.03/share) vs net loss $4.3M in Q2 2024; adjusted net loss $3.7M vs $2.8M.","Adjusted EBITDA loss $2.6M vs $2.2M in Q2 2024; cash $11.7M at quarter end.","FDA appeal for DrugSorb-ATR held in July; administrative review expected by end of August 2025.","Health Canada reconsideration filed; will proceed after FDA decision."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-25-002927","json":"https://secwatch.observer/filing/0000929638-25-002927.json","markdown":"https://secwatch.observer/filing/0000929638-25-002927.md","text":"https://secwatch.observer/filing/0000929638-25-002927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000092963825002927/0000929638-25-002927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000092963825002927/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:08:19.253956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}